This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lien, E. A. Articles by Ueland, P. M. Search for Related Content PubMed PubMed Citation Articles by Lien, E. A. Articles by Ueland, P. M.

Distribution of Tamoxifen and Its Metabolites in Rat and Human Tissues during Steady-State Treatment¹

Department of Pharmacology and Toxicology [E. A. L., E. S.] and Clinical Pharmacology Unit, Department of Pharmacology and Toxicology [P. M. U.], University of Bergen, N-5021, Bergen, Norway

A procedure for the extraction of tamoxifen and metabolites from various rat and human tissues was developed and verified. With this method, we determined the drug and metabolite concentrations during one dosing interval in various tissues (brain, fat, liver, heart, lung, kidney, uterus, and testes) of rats given tamoxifen once daily for 3 or 14 days, and in various normal and malignant tissues obtained during surgery or at autopsy from patients with breast cancer treated with tamoxifen.

In the rat, the concentrations of tamoxifen and metabolites in most tissues were 8- to 70-fold higher than in serum. The highest levels were observed in lung and liver; substantial amounts were also recovered from kidney and fat. Fluctuations of metabolites and tamoxifen content in most tissues were observed during one dosing interval, corresponding to a ratio of 4:8 between C_max and C_min, except in fat and testicular tissues, where the drug concentrations were relatively stable. In addition to tamoxifen, N-desmethyltamoxifen, followed by 4-hydroxytamoxifen, 4-hydroxy-N-desmethyltamoxifen, and N-desdimethyltamoxifen, were abundant in most tissues. In contrast, adipose tissue contained only small amounts of these metabolites.

The concentrations of tamoxifen and metabolites found in human normal and malignant tissues confirmed and extended the conclusions made in the experiments with rats. In humans, levels were 10- to 60-fold higher in tissues than in serum, and relatively high concentrations were detected in liver and lung. Additionally, pancreas, pancreatic tumor, and brain metastases from breast cancer and primary breast cancer retained large amounts of drug. Again, the amounts of demethylated and hydroxylated metabolites were high in most tissues, except in fat. Tamoxifen and some metabolites were also present in specimens of skin and bone tissue. In one patient, significant amounts of drugs could be detected in lung, heart, ovary, and intestinal wall 14 months after withdrawal of tamoxifen, demonstrating efficient retention and slow washout of these compounds in human tissue.

¹ This work was supported by grants from the Norwegian Cancer Society, the Michael Irgens Flocks legat, and Torsteds legat.

² To whom requests for reprints should be addressed.

Received 3/25/91. Accepted 6/25/91.

This article has been cited by other articles:

				R. S. Sane, D. J. Buckley, A. R. Buckley, S. C. Nallani, and P. B. Desai Role of Human Pregnane X Receptor in Tamoxifen- and 4-Hydroxytamoxifen-Mediated CYP3A4 Induction in Primary Human Hepatocytes and LS174T Cells Drug Metab. Dispos., May 1, 2008; 36(5): 946 - 954. [Abstract] [Full Text] [PDF]

				J. Liu, W. Lu, D. Reigada, J. Nguyen, A. M. Laties, and C. H. Mitchell Restoration of Lysosomal pH in RPE Cells from Cultured Human and ABCA4-/- Mice: Pharmacologic Approaches and Functional Recovery Invest. Ophthalmol. Vis. Sci., February 1, 2008; 49(2): 772 - 780. [Abstract] [Full Text] [PDF]

				J. Gjerde, M. Hauglid, H. Breilid, S. Lundgren, J. E. Varhaug, E. R. Kisanga, G. Mellgren, V. M. Steen, and E. A. Lien Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism Ann. Onc., January 1, 2008; 19(1): 56 - 61. [Abstract] [Full Text] [PDF]

				C. MAES, T. KOBAYASHI, and H. M. KRONENBERG A Novel Transgenic Mouse Model to Study the Osteoblast Lineage in Vivo Ann. N.Y. Acad. Sci., November 1, 2007; 1116(1): 149 - 164. [Abstract] [Full Text] [PDF]

				D. C. Miguel, J. K. U. Yokoyama-Yasunaka, W. K. Andreoli, R. A. Mortara, and S. R. B. Uliana Tamoxifen is effective against Leishmania and induces a rapid alkalinization of parasitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes J. Antimicrob. Chemother., September 1, 2007; 60(3): 526 - 534. [Abstract] [Full Text] [PDF]

				I. Larosche, P. Letteron, B. Fromenty, N. Vadrot, A. Abbey-Toby, G. Feldmann, D. Pessayre, and A. Mansouri Tamoxifen Inhibits Topoisomerases, Depletes Mitochondrial DNA, and Triggers Steatosis in Mouse Liver J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 526 - 535. [Abstract] [Full Text] [PDF]

				Y. C. Lim, L. Li, Z. Desta, Q. Zhao, J. M. Rae, D. A. Flockhart, and T. C. Skaar Endoxifen, a Secondary Metabolite of Tamoxifen, and 4-OH-Tamoxifen Induce Similar Changes in Global Gene Expression Patterns in MCF-7 Breast Cancer Cells J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 503 - 512. [Abstract] [Full Text] [PDF]

				P. I. Moreira, J. Custodio, A. Moreno, C. R. Oliveira, and M. S. Santos Tamoxifen and Estradiol Interact with the Flavin Mononucleotide Site of Complex I Leading to Mitochondrial Failure J. Biol. Chem., April 14, 2006; 281(15): 10143 - 10152. [Abstract] [Full Text] [PDF]

				H. Yamaya, M. Saeki, K.-i. Yoshida, J. Shibata, S. Yano, Y. Sato, A. Takao, T. Shindo, A. U. Buzdar, and S. Nagayama DISTRIBUTION OF (7{alpha})-21-[4-[(DIETHYLAMINO) METHYL]-2-METHOXYPHENOXY]-7-METHYL-19-NORPREGNA-1,3,5(10)-TRIEN-3-OL-20-[14C]2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE ([14C]TAS-108) AND ITS METABOLITES AFTER SINGLE ORAL ADMINISTRATION TO RATS BEARING 7,12-DIMETHYLBENZ({alpha})ANTHRACENE-INDUCED MAMMARY TUMOR Drug Metab. Dispos., February 1, 2006; 34(2): 331 - 338. [Abstract] [Full Text] [PDF]

				M. P. Goetz, J. M. Rae, V. J. Suman, S. L. Safgren, M. M. Ames, D. W. Visscher, C. Reynolds, F. J. Couch, W. L. Lingle, D. A. Flockhart, et al. Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes J. Clin. Oncol., December 20, 2005; 23(36): 9312 - 9318. [Abstract] [Full Text] [PDF]

				P. R. Hutson, R. R. Love, T. C. Havighurst, E. Rogers, and J. F. Cleary Effect of Exemestane on Tamoxifen Pharmacokinetics in Postmenopausal Women Treated for Breast Cancer Clin. Cancer Res., December 15, 2005; 11(24): 8722 - 8727. [Abstract] [Full Text] [PDF]

				S. Y. Kim, Y. R. S. Laxmi, N. Suzuki, K. Ogura, T. Watabe, M. W. Duffel, and S. Shibutani FORMATION OF TAMOXIFEN-DNA ADDUCTS VIA O-SULFONATION, NOT O-ACETYLATION, OF {alpha}-HYDROXYTAMOXIFEN IN RAT AND HUMAN LIVERS Drug Metab. Dispos., November 1, 2005; 33(11): 1673 - 1678. [Abstract] [Full Text] [PDF]

				B. Van Den Bossche and C. Van de Wiele Receptor Imaging in Oncology by Means of Nuclear Medicine: Current Status J. Clin. Oncol., September 1, 2004; 22(17): 3593 - 3607. [Abstract] [Full Text] [PDF]

				Z. Desta, B. A. Ward, N. V. Soukhova, and D. A. Flockhart Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6 J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1062 - 1075. [Abstract] [Full Text] [PDF]

				E. A. Lien, P. M. Ueland, and P. E. Lonning Re: Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine J Natl Cancer Inst, June 2, 2004; 96(11): 884 - 884. [Full Text] [PDF]

				V. Stearns, M. D. Johnson, J. M. Rae, A. Novielli, P. Bhargava, D. F. Hayes, Z. Desta, and D. A. Flockhart RESPONSE: Re: Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine J Natl Cancer Inst, June 2, 2004; 96(11): 884 - 885. [Full Text] [PDF]

				E. R. Kisanga, J. Gjerde, A. Guerrieri-Gonzaga, F. Pigatto, A. Pesci-Feltri, C. Robertson, D. Serrano, G. Pelosi, A. Decensi, and E. A. Lien Tamoxifen and Metabolite Concentrations in Serum and Breast Cancer Tissue during Three Dose Regimens in a Randomized Preoperative Trial Clin. Cancer Res., April 1, 2004; 10(7): 2336 - 2343. [Abstract] [Full Text] [PDF]

				E. A. Martin, K. Brown, M. Gaskell, F. Al-Azzawi, R. C. Garner, D. J. Boocock, E. Mattock, D. W. Pring, K. Dingley, K. W. Turteltaub, et al. Tamoxifen DNA Damage Detected in Human Endometrium Using Accelerator Mass Spectrometry Cancer Res., December 1, 2003; 63(23): 8461 - 8465. [Abstract] [Full Text] [PDF]

				J. He, M. E. Kargacin, G. J. Kargacin, and C. A. Ward Tamoxifen inhibits Na+ and K+ currents in rat ventricular myocytes Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H661 - H668. [Abstract] [Full Text] [PDF]

				A. Decensi, C. Robertson, G. Viale, F. Pigatto, H. Johansson, E. R. Kisanga, P. Veronesi, R. Torrisi, M. Cazzaniga, S. Mora, et al. A Randomized Trial of Low-Dose Tamoxifen on Breast Cancer Proliferation and Blood Estrogenic Biomarkers J Natl Cancer Inst, June 4, 2003; 95(11): 779 - 790. [Abstract] [Full Text] [PDF]

				P. B. Desai, S. C. Nallani, R. S. Sane, L. B. Moore, B. J. Goodwin, D. J. Buckley, and A. R. Buckley Induction of Cytochrome P450 3A4 in Primary Human Hepatocytes and Activation of the Human Pregnane X Receptor by Tamoxifen and 4-Hydroxytamoxifen Drug Metab. Dispos., May 1, 2002; 30(5): 608 - 612. [Abstract] [Full Text] [PDF]

				Y. H. Ju, D. R. Doerge, K. F. Allred, C. D. Allred, and W. G. Helferich Dietary Genistein Negates the Inhibitory Effect of Tamoxifen on Growth of Estrogen-dependent Human Breast Cancer (MCF-7) Cells Implanted in Athymic Mice Cancer Res., May 1, 2002; 62(9): 2474 - 2477. [Abstract] [Full Text] [PDF]

				A. GUERRIERI-GONZAGA, A. GALLI, N. ROTMENSZ, and A. DECENSI The Italian Breast Cancer Prevention Trial with Tamoxifen: Findings and New Perspectives Ann. N.Y. Acad. Sci., December 1, 2001; 949(1): 113 - 122. [Abstract] [Full Text] [PDF]

				A. Guerrieri-Gonzaga, L. Baglietto, H. Johansson, B. Bonanni, C. Robertson, M.-T. Sandri, L. Canigiula, C. Lampreda, S. Diani, E. A. Lien, et al. Correlation between Tamoxifen Elimination and Biomarker Recovery in a Primary Prevention Trial Cancer Epidemiol. Biomarkers Prev., September 1, 2001; 10(9): 967 - 970. [Abstract] [Full Text] [PDF]

				S. Mandlekar, V. Hebbar, K. Christov, and A-N. T. Kong Pharmacodynamics of Tamoxifen and Its 4-Hydroxy and N-Desmethyl Metabolites: Activation of Caspases and Induction of Apoptosis in Rat Mammary Tumors and in Human Breast Cancer Cell Lines Cancer Res., December 1, 2000; 60(23): 6601 - 6606. [Abstract] [Full Text]

				C. K. Osborne and S. A. W. Fuqua Selective Estrogen Receptor Modulators: Structure, Function, and Clinical Use J. Clin. Oncol., September 17, 2000; 18(17): 3172 - 3186. [Abstract] [Full Text] [PDF]

				A. Umemoto, Y. Monden, M. Suwa, Y. Kanno, M. Suzuki, C.-X. Lin, Y. Ueyama, Md.A. Momen, A. Ravindernath, S. Shibutani, et al. Identification of hepatic tamoxifen-DNA adducts in mice: {alpha}-(N2-deoxyguanosinyl)tamoxifen and {alpha}-(N2-deoxyguanosinyl)tamoxifen N-oxide Carcinogenesis, September 1, 2000; 21(9): 1737 - 1744. [Abstract] [Full Text] [PDF]

				K. Brown, R. T. Heydon, R. Jukes, I. N.H. White, and E. A. Martin Further characterization of the DNA adducts formed in rat liver after the administration of tamoxifen, N-desmethyltamoxifen or N,N-didesmethyltamoxifen Carcinogenesis, October 1, 1999; 20(10): 2011 - 2016. [Abstract] [Full Text] [PDF]

				A. Decensi, S. Gandini, A. Guerrieri-Gonzaga, H. Johansson, L. Manetti, B. Bonanni, M. T. Sandri, A. Barreca, A. Costa, C. Robertson, et al. Effect of Blood Tamoxifen Concentrations on Surrogate Biomarkers in a Trial of Dose Reduction in Healthy Women J. Clin. Oncol., September 1, 1999; 17(9): 2633 - 2633. [Abstract] [Full Text] [PDF]

				M. C. Chamberlain and P. A. Kormanik Salvage Chemotherapy With Tamoxifen for Recurrent Anaplastic Astrocytomas Arch Neurol, June 1, 1999; 56(6): 703 - 708. [Abstract] [Full Text] [PDF]

				F. A. Beland, L. P. McDaniel, and M. M. Marques Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo Carcinogenesis, March 1, 1999; 20(3): 471 - 477. [Abstract] [Full Text] [PDF]

				D. C. Schwenke, J. D. Wagner, and M. R. Adams In vitro lipid peroxidation of LDL from postmenopausal cynomolgus macaques treated with female hormones J. Lipid Res., February 1, 1999; 40(2): 235 - 244. [Abstract] [Full Text]

				G. B. Anker, H. Refsum, P. M. Ueland, D. C. Johannessen, E. A. Lien, and P. E. Lonning Influence of Aromatase Inhibitors on Plasma Total Homocysteine in Postmenopausal Breast Cancer Patients Clin. Chem., February 1, 1999; 45(2): 252 - 256. [Abstract] [Full Text] [PDF]

				C. K. Osborne Tamoxifen in the Treatment of Breast Cancer N. Engl. J. Med., November 26, 1998; 339(22): 1609 - 1618. [Full Text] [PDF]

				S. Caltagirone, F. O. Ranelletti, A. Rinelli, N. Maggiano, A. Colasante, P. Musiani, F. B. Aiello, and M. Piantelli Interaction with Type II Estrogen Binding Sites and Antiproliferative Activity of Tamoxifen and Quercetin in Human Non-Small-Cell Lung Cancer Am. J. Respir. Cell Mol. Biol., July 1, 1997; 17(1): 51 - 59. [Abstract] [Full Text]